Notice of Results
09 September 2008 - 4:00PM
UK Regulatory
Entelos Inc.
ENTELOS, INC.
NOTICE OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2008
Results Date: 23 September 2008
Entelos, Inc. (LSE: ENTL), a leading life sciences company applying predictive
technologies and "virtual humans" to accelerate drug development and improve the
quality of health-related products, announces that it will be releasing its
interim results for the six months ended 30 June 2008 on Tuesday 23 September
2008.
Analyst Briefing:
An Analyst briefing will be held at 10:00 am on 23 September at the offices of
Buchanan Communications, 45 Moorfields, London, EC2.
For further information please contact:
Entelos, Inc.
James Karis, President and CEO Tel: +1-650-572-5400
Jill Fujisaki, Vice President, Investor
Relations
Buchanan Communications
Lisa Baderoon / Mary-Jane Johnson Tel +44-0-20-7466-5000
About Entelos
Entelos, Inc. (www.entelos.com) is a US-based life sciences company applying
next-generation predictive technologies to revolutionize the way medicines are
discovered, developed, and utilized. The Company leverages its proprietary in
silico disease models, "virtual human" technology, and toxicology reference
systems to develop safer and more effective drugs, improve the quality of
health-related consumer products, and deliver on the promise of personalized
medicine. Entelos provides customized products, technology and research services
to global pharmaceutical, health-care, and consumer products companies in safety
testing, arthritis, cardiovascular diseases, asthma, obesity, diabetes,
hematopoeisis (anemia), cholesterol metabolism, skin sensitization, and personal
care products.
Entelos Regs (LSE:ENTL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Entelos Regs (LSE:ENTL)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Entelos Regs (London Stock Exchange): 0 recent articles
More Entelos Inc. News Articles